Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation: Heart Failure
Search: search_blue_button Advanced Search
Published Online
on July 6, 2009

Circulation: Heart Failure. 2009
Published online before print July 6, 2009, doi: 10.1161/CIRCHEARTFAILURE.108.818237
A more recent version of this article appeared on September 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow Supplemental Data
Right arrow All Versions of this Article:
2/5/456    most recent
CIRCHEARTFAILURE.108.818237v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Dyer, E. C.
Right arrow Articles by Marston, S. B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dyer, E. C.
Right arrow Articles by Marston, S. B.
Related Collections
Right arrow Contractile function
Right arrow Heart failure - basic studies
Right arrow Myocardial cardiomyopathy disease
Right arrow Genetics of cardiovascular disease

Original Article

Functional Analysis of a Unique Troponin C Mutation, Gly159Asp that Causes Familial Dilated Cardiomyopathy, Studied in Explanted Heart Muscle.

Emma C. Dyer1; Adam M. Jacques1; Anita C. Hoskins2; Douglas G. Ward3; Clare E. Gallon1; Andrew E. Messer1; Juan Pablo Kaski4; Michael Burch5; Jonathan C. Kentish2 and Steven B. Marston1,6

1 Imperial College London, London, UK;
2 King's College London, London, UK;
3 University of Birmingham, Birmingham, UK;
4 University College London, London, UK;
5 Great Ormond Street Hospital, London, UK

6 E-mail: s.marston{at}imperial.ac.uk

Background—Familial dilated cardiomyopathy (DCM) can be caused by mutations in the proteins of the muscle thin filament. In vitro these mutations decrease Ca2+-sensitivity and crossbridge turnover rate but the mutations have not been investigated in human tissue. We have studied the Ca2+-regulatory properties of myocytes and troponin extracted from the explanted heart of a patient with inherited DCM due to the cTnC G159D mutation.

Methods and Results—Mass spectroscopy showed that the mutant cTnC was expressed approximately equimolar with wild-type cTnC. Contraction was compared in skinned ventricular myocytes from the cTnC G159D patient and non-failing donor heart. Maximal Ca2+-activated force was similar in cTnC G159D and donor myocytes but the Ca2+-sensitivity of cTnC G159D myocytes was higher (EC50 G159D/donor = 0.60). Thin filaments reconstituted with skeletal muscle actin and human cardiac tropomyosin and troponin were studied by in vitro motility assay. Thin filaments containing the mutation had a higher Ca2+-sensitivity (EC50 G159D/donor = 0.55±0.13) whilst the maximally activated sliding speed was unaltered. In addition, the cTnC G159D mutation blunted the change in Ca2+ sensitivity when TnI was dephosphorylated. With wild-type troponin, Ca2+-sensitivity was increased (EC50 P/unP = 4.7±1.9) but not with cTnC G159D troponin (EC50 P/unP = 1.2±0.1).

Conclusion—We propose that uncoupling of the relationship between phosphorylation and Ca2+-sensitivity could be the cause of the DCM phenotype. The differences between these data and previous in vitro results show that native phosphorylation of troponin I and troponin T and other post-translational modifications of sarcomeric proteins strongly influence the functional effects of a mutation.

Key Words: cardiomyopathy • contractility • heart failure